Despite general economic uncertainty, shares in Ergomed (LON:ERGO) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential to break-out as...
ERGO — Ergomed Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid CapFalling Star
- £472.91m
- £444.35m
- £118.58m
- 92
- 17
- 40
- 45
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.62 | ||
| PEG Ratio (f) | 1.48 | ||
| EPS Growth (f) | 17.14% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.03 | ||
| Price to Tang. Book | 13.25 | ||
| Price to Free Cashflow | 26.72 | ||
| Price to Sales | 3.99 | ||
| EV to EBITDA | 22.59 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.71% | ||
| Return on Equity | 21.1% | ||
| Operating Margin | 12.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 47.62 | 54.11 | 68.25 | 86.39 | 118.58 | 137.97 | 159.06 | 24.76% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +39.52 | +66.36 | +22.52 | +12.21 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for ERGO
Studies by leading experts into the power of price momentum show that stocks with the strongest price trends can potentially keep up the pace for anywhere up to one year. A big part of the reason for this is down to investor psychology...
'Buy' and 'sell' recommendations from company analysts often catch the attention of investors - but it's worth remembering that city experts can get things wrong. So rather than relying on just one recommendation, a potentially better...
Despite economic uncertainty and market volatility, shares in Ergomed (LON:ERGO) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential t...
The good news for any holders of Ergomed (LON:ERGO) is that the price is currently trading close to a 52 week high, with the share price up by around 26.5% to 1304.4625 over the past week. For investors holding the stock (or consideri...
Profile Summary
Ergomed plc is primarily focused on providing services to the biopharmaceutical industry. The Company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The Company operates approximately 24 offices around the world, providing its services in over 100 countries globally. It operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include Ergomed GmbH, Ergomed Sp. z o.o, Ergomed d.o.o. Beograd, Ergomed Clinical Research Inc., MS Clinical Services, LLC and MedSource UK Ltd.
Directors
- Miroslav Reljanovic CHM (63)
- Richard Barfield CFO
- Mark Enyedy NED (57)
- Llew Keltner NED (67)
- Michael Spiteri NID (59)
- Last Annual
- December 31st, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- September 29th, 2000
- Public Since
- July 15th, 2014
- No. of Employees
- 1,255
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 49,519,629
- Address
- 1 Occam Court, Occam Road, GUILDFORD, GU2 7HJ
- Web
- http://www.ergomedplc.com/
- Phone
- +44 1483503205
- Auditors
- KPMG
Latest News for ERGO
Upcoming Events for ERGO
Half Year 2022 Ergomed PLC Earnings Release
Similar to ERGO
4Basebio
London Stock Exchange
4d Pharma
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
FAQ
What is the Ergomed share price?
As of Today at 13:08 UTC, shares in Ergomed are trading at 955.00p. This share price information is delayed by 15 minutes.
How has the Ergomed share price performed this year?
Shares in Ergomed last closed at 955.00p and the price had moved by -25.97% over the past 365 days. In terms of relative price strength the Ergomed share price has underperformed the FTSE All Share Index by -24.19% over the past year.
What are the analyst and broker recommendations for Ergomed?
The overall consensus recommendation for Ergomed is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ergomed dividend yield?
Ergomed does not currently pay a dividend.
Does Ergomed pay a dividend?
Ergomed does not currently pay a dividend.
When does Ergomed next pay dividends?
Ergomed does not currently pay a dividend.
How do I buy Ergomed shares?
To buy shares in Ergomed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ergomed?
As of the previous close price of 955.00p, shares in Ergomed had a market capitalisation of £472.91m.
Where are Ergomed shares listed?
Here are the trading details for Ergomed:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: ERGO
What kind of share is Ergomed?
Based on an overall assessment of its quality, value and momentum Ergomed is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ergomed share price forecast for 2022?
The analyst consensus target price for shares in Ergomed is 1,525.00p. That is 59.69% above the last closing price of 955.00p.
Analysts covering Ergomed currently have a consensus Earnings Per Share (EPS) forecast of £0.42 for the next financial year.
What is the trend in the Ergomed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ergomed. Over the past six months, its share price has underperformed the FTSE All Share Index by -29.75%.
As of the last closing price of 955.00p, shares in Ergomed were trading -25.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ergomed PE Ratio?
The Ergomed PE ratio based on its reported earnings over the past 12 months is 21.62. The shares last closed at 955.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ergomed?
Ergomed's management team is headed by:
- Miroslav Reljanovic - CHM
- Richard Barfield - CFO
- Mark Enyedy - NED
- Llew Keltner - NED
- Michael Spiteri - NID